Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights

EVANSTON, Ill.--(BUSINESS WIRE)--Nov 8, 2022--

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2022 and provided key business updates across the company’s clinical-stage pipeline of novel NMDA receptor modulators.

“During the quarter, we took decisive steps to focus our resources on enabling data readouts from our ongoing clinical studies and maintaining cash runway into 2024,” said Andy Kidd, M.D., president and chief executive officer of Aptinyx. “Our pipeline continues to progress towards meaningful data catalysts next year, beginning with our Phase 2 study of NYX-458 in cognitive impairment associated with Parkinson’s disease. The study is robustly designed to characterize the therapeutic effects of NYX-458 and will measure improvements in cognitive deficits that impact nearly half of all patients with Parkinson’s disease. We look forward to reporting data from this study in the first quarter of next year, as well as to data from our Phase 2b study of NYX-783 in PTSD expected later in the year. We are also pleased to be expanding our pipeline through the clinical evaluation of NYX-783 in opioid use disorder, to be conducted by skilled researchers at Yale University School of Medicine and funded by an NIH grant.”

Recent Business Highlights